Has anyone dealt with a1c reduction on semaglutide: sustain program meta-analysis?

paige_pharma said:

Relative and absolute effects need reading together.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Correct me if the detail matters more than I have assumed.

jennifer_SEA said:

The dose-response is real but shallow at the top.

This answered a question I did not know how to ask. I will report back once I have actually tried it.

paige_pharma said:

Relative and absolute effects need reading together.

I read this differently from paige_pharma, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

One concrete data point for the thread. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Carry on.